{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T12:12:43Z","timestamp":1775477563132,"version":"3.50.1"},"reference-count":20,"publisher":"BMJ","issue":"7","funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,6,9]]},"published-print":{"date-parts":[[2017,7]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>High intrapatient variability (IPV) in tacrolimus trough levels has been shown to be associated with higher rates of renal transplant failure. There is no consensus on what level of IPV constitutes a risk of graft loss. The establishment of such a threshold could help to guide clinicians in identifying at-risk patients to receive targeted interventions to improve IPV and thus outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods and analysis<\/jats:title><jats:p>A multicentre Transplant Audit Collaborative has been established to conduct a retrospective study examining tacrolimus IPV and renal transplant outcomes. Patients in receipt of a renal transplant at participating centres between 2009 and 2014 and fulfilling the inclusion criteria will be included in the study. The aim is to recruit a minimum of 1600 patients with follow-up spanning at least 2 years in order to determine a threshold IPV above which a renal transplant recipient would be considered at increased risk of graft loss. The study also aims to determine any national or regional trends in IPV and any demographic associations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ethics and dissemination<\/jats:title><jats:p>Consent will not be sought from patients whose data are used in this study as no additional procedures or information will be required from participants beyond that which would normally take place as part of clinical care. The study will be registered locally in each participating centre in line with local research and development protocols. It is anticipated that the results of this audit will be disseminated locally, in participating NHS Trusts, through national and international meetings and publications in peer-reviewed journals.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bmjopen-2017-016144","type":"journal-article","created":{"date-parts":[[2017,7,30]],"date-time":"2017-07-30T00:10:21Z","timestamp":1501373421000},"page":"e016144","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Impact of intrapatient variability (IPV) in tacrolimus trough levels on long-term renal transplant function: multicentre collaborative retrospective cohort study protocol"],"prefix":"10.1136","volume":"7","author":[{"given":"Petra M","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew J","family":"Bottomley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Okidi","family":"Okechukwu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria C","family":"Ross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Ghita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Wandless","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart J","family":"Falconer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Papachristos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Nash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vitaliy","family":"Androshchuk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,7,28]]},"reference":[{"key":"2024051613300104000_7.7.e016144.1","first-page":"108","article-title":"Immunosuppressive agents in organ transplantation: past, present, and future","volume":"20","author":"Hong","year":"2000","journal-title":"Semin Nephrol"},{"key":"2024051613300104000_7.7.e016144.2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38569.471007.AE"},{"key":"2024051613300104000_7.7.e016144.3","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med Overseas Ed"},{"key":"2024051613300104000_7.7.e016144.4","doi-asserted-by":"publisher","DOI":"10.1517\/14622416.6.4.323"},{"key":"2024051613300104000_7.7.e016144.5","unstructured":"http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR__Product_Information\/human\/000712\/WC500022234.pdf3EMA: EMA\/618604\/2008. (10 Dec 2012)"},{"key":"2024051613300104000_7.7.e016144.6","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03791106"},{"key":"2024051613300104000_7.7.e016144.7","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-199529060-00003"},{"key":"2024051613300104000_7.7.e016144.8","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1365-2125.2007.02888.x","article-title":"Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients","volume":"64","author":"Antignac","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"2024051613300104000_7.7.e016144.9","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0b013e3181aa36cd"},{"key":"2024051613300104000_7.7.e016144.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00352.x"},{"key":"2024051613300104000_7.7.e016144.11","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000258599.65257.a6"},{"key":"2024051613300104000_7.7.e016144.12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/FTD.0b013e31821a7aa3","article-title":"CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance","volume":"33","author":"Pashaee","year":"2011","journal-title":"Ther Drug Monit"},{"key":"2024051613300104000_7.7.e016144.13","doi-asserted-by":"publisher","DOI":"10.2165\/11317350-000000000-00000"},{"key":"2024051613300104000_7.7.e016144.14","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2011.165613"},{"key":"2024051613300104000_7.7.e016144.15","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/17.7.1310"},{"key":"2024051613300104000_7.7.e016144.16","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/TP.0b013e31822dc34f","article-title":"Monitoring nonadherence and acute rejection with variation in blood immunosuppressant levels in pediatric renal transplantation","volume":"92","author":"Hsiau","year":"2011","journal-title":"Transplantation"},{"key":"2024051613300104000_7.7.e016144.17","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/TP.0000000000001129","article-title":"High intrapatient tacrolimus variability is associated with worse outcomes in renal transplantation using a low-dose tacrolimus immunosuppressive regime","volume":"101","author":"Whalen","year":"2017","journal-title":"Transplantation"},{"key":"2024051613300104000_7.7.e016144.18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.trre.2015.01.002","article-title":"Intra-patient variability in tacrolimus exposure: causes, consequences for clinical management","volume":"29","author":"Shuker","year":"2015","journal-title":"Transplant Rev"},{"key":"2024051613300104000_7.7.e016144.19","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/ki.2013.465","article-title":"Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure","volume":"85","author":"Sapir-Pichhadze","year":"2014","journal-title":"Kidney Int"},{"key":"2024051613300104000_7.7.e016144.20","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq096"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2017-016144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,16]],"date-time":"2024-05-16T20:33:42Z","timestamp":1715891622000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2017-016144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":20,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2017,7,28]]},"published-print":{"date-parts":[[2017,7]]}},"alternative-id":["10.1136\/bmjopen-2017-016144"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2017-016144","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}